Peptide And Anticoagulant Drugs Global Market Report 2025

The peptide and anticoagulant drugs market size has grown at grown rapidly in recent years. It will grow from $1.41 billion in 2024 to $1.56 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to increased healthcare expenditure, rising healthcare investments, market liberalization, a growing number of infected patients worldwide, and a higher incidence of genetic conditions.

The peptide and anticoagulant drugs market size is expected to see rapid growth in the next few years. It will grow to $2.3 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth during the forecast period can be attributed to the rising prevalence of chronic diseases, an aging population, increasing cancer cases, the expansion of emerging markets, and the growing burden of cardiovascular diseases. Key trends expected during this period include advancements in biotechnology, technological developments in drug delivery, improved diagnostic techniques, innovations in pharmacology, and the development of new anticoagulant products.

The increasing prevalence of chronic diseases is expected to drive the growth of the peptide and anticoagulant drugs market. Chronic diseases are long-term health conditions that persist for years or even a lifetime. Factors such as aging populations, unhealthy lifestyles, and a rise in risk factors such as obesity, hypertension, and diabetes contribute to the growing burden of chronic diseases. Peptide and anticoagulant drugs play a crucial role in managing conditions such as cardiovascular diseases, thrombosis, and stroke by preventing blood clots and targeting specific disease pathways for better patient outcomes. For example, in May 2023, reports from the Centers for Disease Control and Prevention (CDC) indicated that heart disease and cancer deaths reached 695,547 in 2022, an increase from 605,213 in 2021. As a result, the rising prevalence of chronic diseases is fueling the expansion of the peptide and anticoagulant drugs market.

Companies in the peptide and anticoagulant drugs market are focusing on advancements in anticoagulant therapies, such as oral anticoagulants, to enhance efficacy, improve patient compliance, and reduce the risk of bleeding complications. Oral anticoagulants are medications taken by mouth to prevent blood clots by inhibiting clotting factors in the blood. For instance, in April 2024, Cadrenal Therapeutics Inc., a US-based pharmaceutical company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for tecarfarin, its late-stage oral anticoagulant. Tecarfarin is a novel, reversible blood thinner designed to reduce the risk of heart attacks, strokes, and mortality associated with blood clots in patients with rare cardiovascular conditions. The ODD applies specifically to preventing thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), ventricular assist devices (VADs), biventricular assist devices, and total artificial hearts.

In September 2023, Biosynth, a Switzerland-based provider of complex chemicals and biological materials, acquired Pepceuticals for an undisclosed amount. This acquisition aims to strengthen Biosynth’s capabilities in developing and manufacturing peptide-based therapeutics and biomaterials. The strategic move expands Biosynth’s presence in the life sciences sector, offering a broader portfolio of advanced solutions for the pharmaceutical and biotechnology industries. Pepceuticals Ltd is a UK-based manufacturer specializing in synthetic peptides.

Major players in the peptide and anticoagulant drugs market are Pfizer Inc., Merck & Co. Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Sanofi S.A., Abbott Laboratories, Novartis AG, Novo Nordisk A/S, Viatris Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Bachem Holding AG, Bharat Serums and Vaccines Limited, Wockhardt Limited, AmbioPharm Inc., MITS Healthcare Private Limited, Siddha Pharmacy, Circle Pharma Inc., and Tenwel Pharmaceuticals Pvt. Ltd.

North America was the largest region in the peptide and anticoagulant drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peptide and anticoagulant drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peptide and anticoagulant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Peptide and anticoagulant drugs are therapeutic agents where peptide drugs are short chains of amino acids that mimic natural biological molecules, and anticoagulant drugs prevent blood clotting by inhibiting clotting factors. Some anticoagulants, such as hirudin and bivalirudin, are peptide-based, directly inhibiting thrombin to prevent thrombosis. These drugs are crucial in treating conditions such as deep vein thrombosis, pulmonary embolism, and stroke.

The main types of peptide and anticoagulant drugs are hormonal, antibiotic, ACE inhibitor, antifungal, and other types. Hormonal drugs, including peptide-based hormones such as insulin and GLP-1 analogs, regulate hormone levels to treat conditions such as diabetes, while peptide and anticoagulant drugs provide targeted therapies for managing chronic diseases. These drugs can be administered through various routes, including oral, injectable, and other methods, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and others. Their applications span a wide range of medical fields, including infectious diseases, gynecology, cancer, diabetes, cardiology, osteoporosis, and others. End-users of these drugs include hospitals, specialty clinics, home care settings, and others.

The peptide and anticoagulant drugs market research report is one of a series of new reports that provides peptide and anticoagulant drugs market statistics, including the peptide and anticoagulant drugs industry global market size, regional shares, competitors with the peptide and anticoagulant drugs market share, detailed peptide and anticoagulant drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the peptide and anticoagulant drugs industry. This peptide and anticoagulant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peptide and anticoagulant drugs market consists of sales of peptide-based drugs and heparins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.